pTERT C250T mutation: A potential biomarker of poor prognosis in metastatic melanoma-Reference-Cited by-同舟云学术

pTERT C250T mutation: A potential biomarker of poor prognosis in metastatic melanoma

Published:2023-08 Issue:8 Volume:9 Page:e18953
ISSN:2405-8440
Container-title:Heliyon
language:en
Short-container-title:Heliyon

Author:

Blanco-García Leyla,Ruano Yolanda,Blanco Martínez-Illescas Raquel,Cubo Rocío,Jiménez Sánchez Paula,Sánchez-Arévalo Lobo Víctor J.,Riveiro Falkenbach Erica,Ortiz Romero Pablo^ORCID,Garrido María C.,Rodríguez Peralto José L.

Funder

Instituto de Salud Carlos III

Publisher

Elsevier BV

Subject

Multidisciplinary

Reference52 articles.

1. Human cutaneous melanoma; a review of NRAS and BRAF mutation frequencies in relation to histogenetic subclass and body site;Platz;Mol. Oncol.,2008

2. Targeting mutant BRAF in melanoma: current status and future development of combination therapy strategies;Kudchadkar;Cancer J.,2012

3. Intra- and inter-tumoral homogeneity of BRAF V600E mutations in melanoma tumors;Riveiro-Falkenbach;J. Invest. Dermatol.,2015

4. TERT promoter mutations in familial and sporadic melanoma;Horn;Science (80-),2013

5. Highly recurrent TERT promoter mutations in human melanoma;Huang;Science (80-),2013

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Melanoma Brain Metastases Patient-Derived Organoids: An In Vitro Platform for Drug Screening;Pharmaceutics;2024-08-05

2. Using deep learning to decipher the impact of telomerase promoter mutations on the dynamic metastatic morpholome;PLOS Computational Biology;2024-07-30

3. Using Deep Learning to Decipher the Impact of Telomerase Promoter Mutations on the Morpholome;2023-11-21